The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007.
The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007, a treatment for diabetic macular oedema (DME).
iCo-007 is a second generation antisense compound that targets c-Raf kinase messenger RNA and reduces the oedema by decreasing the signalling of growth factors such as VEGF that signal through the c-Raf kinase pathway.
COPHy 2023: The pros and cons of managing AMD with home monitoring
March 25th 2023The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal.
COPHy 2023: Restorative therapies and the path to them
March 24th 2023In a keynote lecture at the 14th Annual Congress on Controversies in Ophthalmology in Lisbon, Hendrik Scholl, MD, co-founder and director of the Institute of Molecular and Clinical Ophthalmology Basel, discussed its mission to unravel the mysteries of vision and human eye disease.
2 Clarke Drive
Cranbury, NJ 08512